MOUNTAIN VIEW Calif., Oct. 12, 2012 – Inscopix, Inc. and SRI International today announced a collaborative neuroscience imaging R&D program. Researchers from Inscopix and SRI’s Center for Neuroscience and Metabolic Diseases will use Inscopix’s nVista™ HD imaging system to gain a better understanding of normal brain function and the dysfunctions of neural circuitry that underlie neurological and neuropsychiatric disorders.
“Inscopix’s nVista HD technology will provide SRI researchers with an unparalleled view into brain activity that underlies both normal and diseased brain function,” said Thomas Kilduff, Ph.D., senior director of SRI’s Center for Neuroscience and Metabolic Diseases. “Since many brain diseases such as Alzheimer’s, autism, and schizophrenia are thought to involve dysfunction of neural circuitry, we expect to obtain novel insights that may lead to new therapeutic avenues for the treatment of neurological and neuropsychiatric disorders.”
SRI’s Center for Neuroscience and Metabolic Diseases has research programs in cognition and Alzheimer’s disease, Parkinson’s disease, sleep neurobiology and sleep disorders, nicotine addiction, alcoholism, and brain aging. Advanced imaging capabilities are needed to obtain a more complete understanding of the neural circuitry that underlies the functional activity of the brain. One research area of the collaborative effort will focus on identifying brain circuits that go awry in disease conditions or in the presence of a gene defect.
“Inscopix is extremely excited to be working with SRI’s Center for Neuroscience and Metabolic Diseases on this collaborative research project,” said Kunal Ghosh, Ph.D., Inscopix CEO. “Inscopix’s continued technology and application development will benefit tremendously via this project. At the same time Inscopix’s scientists are also looking forward to working with SRI’s researchers on pursuing new science uniquely enabled by nVista HD.”
SRI Biosciences and Inscopix are both exhibiting at Neuroscience 2012 (SfN) in New Orleans (booths #736 & #733, respectively).